Project Grant R01AI192148
Award Date 9/12/25
Completion Date 8/31/29
Dollars Obligated $3.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- This federal Project Grant award for $657,907 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a 5-year longitudinal analysis to understand the impact of expanding pharmacists' scope of practice on the uptake and retention of pre-exposure prophylaxis (PrEP) for HIV prevention. The project aims to integrate multiple data sources, including policy, census, survey, and medical claims data, to...
- This $747,000 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund research to determine the effects of pre-exposure prophylactic (PrEP) drugs on female genital HIV infection and women's reproductive health. The research will focus on understanding how PrEP impacts the female reproductive tract microenvironment and any potential...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $250,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the Fred Hutchinson Cancer Center, also known as the Seattle Cancer Care Alliance, to conduct a hybrid effectiveness-implementation cluster-randomized controlled trial across 20 pharmacies in Kenya. The goal of the project is to leverage telehealth to optimize the delivery of pre-exposure prophylaxis (PrEP) and...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- This Project Grant award of $962,973.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop and evaluate a comprehensive curriculum on HIV prevention and implementation science for pharmacy schools in the southern United States. The project, titled "Pharmacists for Prevention (P4P): Harnessing the Role of Pharmacists in Ending the HIV Epidemic through Collaboration with Pharmacy Schools," will be...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- This $731,738 Project Grant awarded by the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) will fund a pilot feasibility study to integrate pre-exposure prophylaxis (PrEP) into emergency department and urgent care settings using a patient-centered decision support tool. The goal is to improve PrEP awareness, access, and uptake among groups at highest risk for acquiring HIV, such as men who have sex with men, young people, racial/ethnic minorities, and women of...
- The University of Washington was awarded a $985,308 Project Grant from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) to advance pharmacy-based delivery of primary sexually transmitted infection (STI) and HIV prevention for cisgender women in Kenya. The funding supports research to evaluate strategies for addressing STIs and promoting HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) uptake...
- This federal Project Grant award of $1,066,077 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant will fund a Type 3 hybrid effectiveness-implementation study to evaluate the "PrEP & Soccer" intervention delivered through CVS pharmacy locations in Miami-Dade, Florida. The intervention aims to increase PrEP knowledge and initial PrEP appointment attendance among...